Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Share:
Related GILD
Benzinga's M&A Chatter for Thursday August 27, 2015
Biogen And Gilead Sciences Catch The Eye Of Short Sellers
How To Handle Market Crashes (Seeking Alpha)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015BarclaysMaintainsOverweight
Jul 2015Bank of AmericaMaintainsUnderperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

Get Benzinga's Newsletters